Van Andel Research Institute Finding Could Lead to Reduced Side Effects in Anti-Cancer Antibiotics

	Tweet

Most of us have had a doctor prescribe an antibiotic for a stubborn bacterial infection, or for a cut that gets infected.  However, prescribing an antibiotic to fight cancer?  In fact, anti-cancer antibiotics have been used since the 1950s to successfully treat several forms of cancer, but often the side effects limit the duration they can be given to a patient.

One particularly promising anti-cancer antibiotic is Geldanamycin and a modified form of this drug known as 17AAG.  Despite its proven ability to selectively kill many different forms of cancer in laboratory studies, the use of these drugs is limited due to side effects, mainly liver failure, in patients.

Newly published results from Van Andel Research Institute (VARI) researchers have determined how the anti-cancer antibiotic Geldanamycin and its derivative 17AAG work in more detail and have uncovered a possible explanation for side effects observed in clinical trials of the drug. 

"The article provides novel and significant information about the clinical potential of these compounds in cancer therapy,” said Yale School of Medicine Professor and Chair of Pharmacology Joseph Schlessinger, Ph.D.

Although there was much preclinical interest in the antibiotic Geldanamycin as an anti-cancer drug, it turned out to be a poor candidate for clinical trials because of its toxicity.  Derivatives such as 17AAG were developed to decrease toxicity and are still being evaluated in clinical trials.

VARI researchers determined how Geldanamycin and 17AAG work in more detail in a study published in Proceedings of the National Academy of Sciences U.S.A., which could inform future drug design, and also found a way to potentially decrease the antibiotics’ toxicity.

“There was so much interest early on in Geldanamycin because it resulted in the degradation of oncoproteins, important protein targets in tumor cells,” said VARI Research Scientist and lead author of the paper Qian Xie, M.D., Ph.D.

“If there is a chance of decreasing the toxicity of Geldanamycin and 17AAG, it would be a boon in the treatment of cancer,” said George Vande Woude, Ph.D., head of the Laboratory of Molecular Oncology at VARI that published the study.

# # #

About Van Andel Institute
Established by Jay and Betty Van Andel in 1996, Van Andel Institute (VAI) is an independent research and educational organization based in Grand Rapids, Mich., dedicated to preserving, enhancing and expanding the frontiers of medical science, and to achieving excellence in education by probing fundamental issues of education and the learning process. Van Andel Education Institute (VAEI) is dedicated to strengthening science education and preparing and motivating individuals to pursue science or science-related professions. Van Andel Research Institute (VARI), the research arm of VAI, is dedicated to probing the genetic, cellular and molecular origins of cancer, Parkinson’s and other diseases and working to translate those findings into effective therapies. This is accomplished through the work of over 200 researchers in 18 on-site laboratories and in collaborative partnerships that span the globe. VARI is affiliated with the Translational Genomics Research Institute, (TGen), of Phoenix, Arizona.

###

Van Andel Institute

RELATED STORIES:
Men: Cancer Prevention Tips By Age   New device could cut chemotherapy deaths   Researchers Identify Cancer Preventive Properties in Common Vitamin Supplement   Mayo Clinic study shows Parkinson’s disease drug might work in cancer patients   Michigan cancer programs follow care guidelines for common cancers, study finds   Oral Form of Anti-cancer Agent Shows Promise in Treating Sarcoma   Simple test could hold key to early diagnosis of cancers   Many cancer survivors still smoking and drinking   Scientists announce new advance with potential for future cancer targeting   Protein Raises Antibody Output   How Infection and Inflammation Can Lead to Cancer   European disparities in access to cancer drugs   Scientists decode secrets of a very common virus that can cause cancer   Nottingham research leads to blood test for early detection of cancer   Using a molecular switch to turn on cancer vaccines   Inhaled morphine eases cancer-related air hunger   Co-ordinating cancer care   Viruses against cancer   Is Grilling Linked to Cancer?   New Study Begins for Kids With High-Risk Cancer   Discovery Could Lead to Early Cancer Detection, Prevention   Gene Therapy Anti-cancer Work Featured in Scientific American

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]